Daxor logo

DXR - Daxor News Story

$10.74 -0.3  -3.0%

Last Trade - 9:10pm

Micro Cap
Market Cap £33.0m
Enterprise Value £34.1m
Revenue £200k
Position in Universe 6092nd / 7405

Daxor Corporation To Present Compelling New Data and Clinical Trials Utilizing the BVA-100® Blood Test at the Heart Failure Society of America Annual Scientific Meeting 2021

Wed 8th September, 2021 1:30pm
For best results when printing this announcement, please click on link below:

Oak Ridge, TN, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daxor
(NYSE: DXR), the global leader in blood volume measurement technology, , today
announced it will exhibit at the Heart Failure Society of America (HFSA)
Annual Scientific Meeting (ASM) 2021 – which brings together the world’s
leading experts in heart failure from September 10-13, 2021. This year’s ASM
provides a hybrid format; in-person at the Gaylord Rockies in Denver, Colorado
or live virtually across the globe.

“This is the strongest HFSA program in Daxor’s history. We are excited to
feature new trials as well as outcome data with clinical partners from leading
institutions,” stated Jonathan Feldschuh, Chief Scientific Officer of Daxor
Corporation. New data highlighting the applicability of blood volume analysis
(BVA) titled, “Value of Blood Volume Analysis in Patients with Left
Ventricular Assist Devices” (Poster #059), “Volume-Guided Venous To Venous
Ultrafiltration in Hospitalized Heart Failure Patients” (Poster #089), and
“The Phenotype of Polycythemia and Hypervolemia in Hospitalized Heart
Failure Patients” (Poster #117) will be featured on-line and in the e-Poster

“The HFSA’s Annual Scientific Meeting is the premier event that gathers
the best scientific minds focused on the latest heart failure science,
research and patient management,” said Michael Feldschuh, CEO of Daxor
Corporation. “We are looking forward to sharing with leaders two landmark
research studies featured in Clinical Trial Row underway including a National
Institute of Health (NIH) funded randomized multicenter control trial with the
U.S. Department of Veterans Affairs applying BVA-100 guided care to improve
hospitalized heart failure outcomes, a patient population of over 1 million
domestically. Equally important is an outpatient prospective randomized trial
for heart failure management featuring next generation technology developed
through contracts awarded by the U.S. Department of Defense and funded by the
Center for Advancing Point of Care Technologies (CAPCaT)/NIH, also measuring
the benefit of the BVA-100 test for improving ambulatory heart failure patient
care, a population that numbers more than 6 million in the U.S. alone.”

The company will be exhibiting at Booth 109.

Register for the event here:

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement
technology focused on blood volume testing innovation. We developed and market
the BVA-100(®) (Blood Volume Analyzer), the first diagnostic blood test
cleared by the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific norms. The
BVA technology enhances hospital performance metrics in a broad range of
surgical and medical conditions, including heart failure and critical care, by
informing treatment strategies, resulting in significantly improved multiple
measures of patient outcomes. Daxor's mission is to advance healthcare by
enabling optimal fluid management with blood volume analysis. Daxor’s vision
is optimal blood volume for all. For more information, please visit our
website at Daxor.com

Forward-Looking Statements

Certain statements in this release may include forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements regarding the impact of hiring sales
staff and expansion of our distribution channels. Forward-looking statements
are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to
risks and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this release,
including, without limitation, those risk associated with our post-market
clinical data collection activities, benefits of our products to patients, our
expectations with respect to product development and commercialization
efforts, our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual property
protection, FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with and benefits
from acquired businesses, and additional other risks and uncertainties
described in our filings with the SEC. Forward-looking statements speak only
as of the date when made. Daxor does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR


GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.